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Chemogenomic profiling of the fungal pathogen Candida albicans 
Alaa Maqnas 
Nosocomial blood stream infections and candidemia caused by the opportunistic fungal 
pathogen, Candida albicans, represent a serious medical problem. Hence, there is a great 
need to better understand the signalling and/or regulatory pathways that confers sensitivity 
and/or resistance to a given class of antifungal agent for this fungal pathogen. The main aim 
of the present study was to use a modified version of the gene replacement and conditional 
expression (GRACE) library to study the interactions between anti-fungal drugs (fluconazole, 
posaconazole and amphotericin B) and a set of non-conditional mutants in non-essential C. 
albicans genes. Further, the utility of using the modified version (GRACE v1.0) of GRACE 
library in comparison to the parent GRACE library was assessed. Overall, my findings 
showed that the chemogenomic profiles within drug classes were highly similar. The small 
amount of overlap between classes suggests that different drug classes interact with discrete 
networks of C. albicans genes. Importantly, my findings also demonstrate that screening of 
compounds, specifically azoles, in GRACE parent library may result in false positive findings 
possibly due to interaction with tetracycline. Future work involving further characterization 
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1. Introduction: Fungal Pathogens 
Virulence involves a complex interplay between a host and a microbe, a phenomenon that is 
particularly evident in fungal pathogenesis [1]. The impact of fungal pathogens on the plant 
and animal species, and associated ecosystem disturbances is well recognized [2, 3]. In 
contrast, the effect of fungal infections on human health is often overlooked with little or no 
mycological surveillance conducted by public health agencies such as World Health 
Organization (WHO) and Centre for Disease Control and Prevention (CDC; United States of 
America) [3]. In fact, billions of people world-wide are infected by pathogenic fungi every 
year, with over million deaths reported annually [3].  
 
The human pathogenic fungi are broadly classified into two groups: commensals or 
opportunistic pathogens, and thermally dimorphic fungi or primary pathogens [1, 4]. The 
commensals such as Candida spp., dermatophytes, Malassezia spp., are normal constituents 
of the human micro-flora that can cause disease when the host defense settings are altered [1]. 
On the other hand, the primary pathogens, including Histoplasma capsulatum, Blastomyces 
dermatitidis, Penicillium marneffei, and Sporothrix schenckii etc., reside in specific 
environmental niches and affect individuals who have either been exposed to the spores or 
small yeast cells or who are immunologically naïve to fungal pathogen [1, 4].  
 
Over the past two decades, there has been a dramatic increase in the incidence and prevalence 
of nosocomial (originating in a hospital) fungal infections [5]. Infections caused by the fungal 
pathogens range from catheter-related localized fungemia to widespread haematogenous 
dissemination, and differ in their nature, distribution and causative agents [6]. Among the 
most deadly fungal pathogens, Candida species (spp.) remains the most important and 
common cause of invasive fungal diseases in humans [5], and is discussed in detail in the 
following sections.   
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1.1 Candida Species 
Candida species are by far the most studied group of opportunistic fungal pathogens and 
remain the most common group encountered in intensive care units, or during organ or bone 
marrow transplantation [8]. To date, more than 100 species of Candida have been described 
[6]. Most of the clinically common Candida spp. are asexual yeasts of phylum ascomycetes 
that are genetically diploid (haploid constitution of eight chromosomes) and capable of 
transitioning between a unicellular yeast form and a filamentous growth form [7]. An 
exception is the haploid C. glabrata which grows only in yeast form [7].  
 
Candida spp. are responsible for causing a large spectrum of diseases, including candidemia 
with or without endopthalmitis, disseminated haematogeneous infections and chronic 
hepatosplenic candidiasis [8]. Importantly, Candida spp. are the third most common cause of 
nosocomial bloodstream infections (BSI) in global adult [9] as well as pediatric populations 
[10]. However, the true prevalence of Candida-related BSIs is often markedly 
underrepresented as the studies predominantly rely only on positivity in blood cultures [5]. 
This is in addition to the fact that the deep-seated pathogens in organs such as bones, muscles, 
joints or eyes often remain undetected [11]. Worldwide, ~75% of women suffer from 
Candida infection at least once in their lifetime [12]. It has been estimated that the healthcare 
costs associated with hematogenously disseminated candidiasis is approximately $2 - 4 
billion per year in United States alone [13]. 
 
Until the early 1990s, predominant Candida infections were caused by C. albicans, which 
was found to adhere avidly to human tissues in vitro [14, 15] and to mammalian tissues in 
preclinical rodent models in vivo [16, 17]. Since then, there has been a steady increase in the 
frequency of non-albicans Candida species causing candidiasis [3, 11, 18]. Among the 160 
species in the genus Candida, recent findings suggest that ~95 – 97% of Candida-associated 
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BSIs in the clinical setting are caused by C. albicans, C. glabrata, C. parapsilosis, C. 
tropicalis and C. krusei [11], with the remaining 3% – 5% cases caused by 12 – 14 species, 
including C. lusitaniae, C. guilliermondii, and C. rugose [6]. Studies have also shown 
differences in the incidence rates of various Candida spp.-related BSI in various countries 
such as Spain [19], Iceland [20], Europe [21-25], United States [10, 13] and Australia [26] 
(reviewed in detail in [12, 18]). The epidemiological differences in the prevalence of these 
species in the clinical setting could be attributed to the differences in demographic 
characteristics, healthcare practices and co-morbidities of patients [8]. In addition, 
considerable differences in the virulence of Candida spp. and other factors such as sensitivity 
to anti-fungal drugs, degree of adherence and propensity to colonize etc. may also play a 
significant role [11]. This epidemiological trend also has profound consequences in the 
selection of anti-fungal therapies [18]. 
 
Overall, recent studies show that C. albicans remain the most common species causing 
invasive candidiasis worldwide and is detected in more than 50% of clinical isolates in 
patients with hematogenous candidiasis, thereby making it a dominating fungal pathogen of 
the genus Candida [12, 27-31].  
1.1.1 Candida albicans 
Historically, C. albicans is known since 400 BC when renowned Greek physicians, 
Hippocrates and Galen, identified oral aphthous lesions and named it as “thrush” [32]. Later 
in the 19th century, Langenbeck discovered a fungi in the gastrointestinal tract of patient [33], 
the etiology of which was subsequently demonstrated by Berg [34]. In 1843, the pathogen 
was named as 'Oidium albicans' by Robin [35] which was later followed by more than 100 
synonyms. It was only in 1923 the pathogen was named as Candida albicans by Berkhout, a 
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denomination currently accepted as the name of this species [36]. The first case of C. 
albicans invasive candidiasis was documented in 1861 [37].    
 
Candida albicans is an opportunistic fungal pathogen that exists as a harmless commensal in 
the oral cavity, skin, gastrointestinal and genitourinary tracts of warm-blooded animals 
including humans [11]. However, in patients with high risk factors, Candida spp. that 
colonize in the gut invade other organs, either through translocation or through anatomical 
leakage, and subsequently cause secondary metastatic infections [11]. The incidence of C. 
albicans induced systemic candidiasis in the United States is approximately 20 cases per 
100,000 people (or about 60,000 cases per year) with the incidence reportedly higher in 
patients who have been hospitalized for longer durations [38]. In spite of the advances in the 
diagnosis and treatment of candidiasis over the past two decades, the infection still causes 
high mortality rates [11, 39]. 
a. Virulence and pathogenicity 
Pathogenicity is the ability of a fungi to adapt to the host environment and defenses, and 
cause harm to the host niches [40]. The pathogenicity of Candida species is attributed to 
various virulence factors, including phenotypic switching, the ability to enter and/or evade 
host defences, the expression of adhesins and invasins, and biofilm formation. These have 
been reviewed in detail in [7, 40-42] and are discussed in brief in the following sections. 
b. Morphogenesis  
The morphological diversity of C. albicans is a striking feature that promotes its survival, 
growth and dissemination in the host [40, 43]. The various morphological forms range from 
unicellular white or opaque budding yeast to true hyphae, with various other forms in the 
transition collectively termed as pseudohyphae [44, 45]. The yeast cells are characterized by 
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polar growth followed by isometric expansion of buds. Polarized growth is defined by a 
crescent-shaped polarisome at the tip of the growing bud [45]. In contrast, buds produced by 
pseudohyphal cells remain attached to the parent even after septum formation resulting in 
filaments with constrictions at the junction of the septa [44, 45]. True hyphae form when an 
unbudded yeast cell extends a germ tube with parallel side-walls, and is defined by both a 
polarisome and a Spitzenkorper [12, 14, 45]. Occasionally, thick-walled cells called 
Chlamydospores are formed in response to stress at the ends of pseudohyphae and hyphae [9, 
43]. 
 
The ability of C. albicans to switch between yeast, hyphal and pseudohyphal forms are often 
considered to be necessary for virulence [44, 46]. It is believed that the filamentous forms,  
(hyphae and pseudohyphae), are uniquely invasive as they express apical hydrolytic enzymes 
[47]  and that the yeast form is more suited for dissemination via the blood stream [46]. But, 
it is also important to recognize that most dimorphic fungi exhibit yeast growth in diseased 
tissues and exist as filamentous fungi in the external environment [44, 46].  
 
Pioneering studies of morphological switching have documented various environmental 
conditions that could trigger the yeast to hyphal formation [48]. These include addition of 
serum, N-acetyl-glucosamine, temperature of 37°C, neutral pH, 5% carbon-dioxide and high 
phosphate concentrations [48]. The role of various signaling pathways and the cell cycle in 
the regulation of morphogenesis have also been elucidated and are discussed in detail 





c. Adhesins and invasins  
Adherence of cells to the host tissues and the subsequent invasion is a complex phenomenon 
utilizing various adhesins and invasins expressed on morphogenetically changing cell 
surfaces [50]. The key part of these initial contact events is the adherence of fungal cells to 
host epithelial cells, whose outcome governs all subsequent interactions between fungus and 
host [25]. Although various adhesins are known, the best characterised, most studied families 
of adhesins are agglutinin-like sequences (ALS) and the hyphal wall protein (Hwp1) [7, 38]. 
Following adherence and recognition of the pathogen by host cells, hyphae are engulfed via a 
clathrin-mediated mechanism. Importantly, the ability to induce this endocytic uptake is 
restricted only to hyphae and not yeast cells [41]. The latter predominantly follow an active 
penetration process involving the Secreted Aspartic Protease (SAP) family. See [33, 41] for 
detailed review on adhesins and invasins. 
d. Mating in C. albicans  
Originally classified as an asexual organism, a novel parasexual reproduction process has 
also been elucidated for C. albicans [50, 51]. The C. albicans genome contains open reading 
frames that are similar to the S. cerevisiae mating-type genes, viz. MATa1, MATα1 and 
MATα2, that are organized into two non-homologous mating-type-like (MTL) loci, MTLa and 
MTLα, on chromosome 5 [51]. However, unlike S. cerevisiae,  a and α cells in C. albicans 
must transform to the relatively unstable opaque form to be mating competent [50, 51]. The C. 
albicans mating locus also contains three additional pairs of genes: PAP, PIK, and OBP [50]. 
The sexual and parasexual reproduction in C. albicans has been reviewed in detail in [50, 51]. 
1.2 ANTI-FUNGAL DRUGS 
Since the early 1950s, there have been significant developments in the discovery of anti-
fungal drugs. However, the efficacy of all of the exiting anti-fungal drugs are often limited by 
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inherent toxicity, emergence of resistance, inability to counteract biofilm formation and/or 
restrictions in drug formulation [38, 52]. Antifungal drug development is complicated by the 
fact that fungal cells are eukaryotic, like the human host, thereby making it much more 
difficult to identify selective pathogen-specific targets for drug discovery programs. In 
addition to this is the difference in sensitivity of various Candida species to the commonly 
used anti-fungal drugs.  
 
Hence, there is a great need to better understand the signalling and/or regulatory pathways 
that facilitate the growth as well as the virulence of this fungal pathogen. The current 
armamentarium for treatment of Candida-BSIs are primarily limited to three classes of 
antifungal drugs; polyenes, azoles and echinocandins [11, 38, 52]. 
1.2.1 Polyenes 
The polyenes, such as amphotericin B and nystatin, were the first class of antifungals to reach 
the clinic [53]. Although amphotericin B was once considered to be the 'gold standard' anti-
fungal therapy, infusion-related adverse effects as well as dose-limiting nephrotoxicity 
limited its use [55]. These molecules bind to the fungal cell membrane sterol, ergosterol, to 
create pores and allow leakage of intracellular ions as well as inhibit membrane transporters 
[56]. At low concentrations of amphotericin B, the channels are permeable only to 
monovalent cations [55]. In contrast, at higher concentrations, the non-aqueous channels 
interact with ergosterol or cholesterol in the cell membrane to form aqueous pores that are 
permeable to both chloride and potassium, resulting in intracellular acidification and 
subsequent membrane damage [55]. Amphotericin B is generally recommended for invasive 
infections such as fungemia, osteomyelitis and chronic disseminated candidiasis, particularly 
for patients with neutropenia or critical illness where the organism has not been identified to 




The discovery of azoles marked a significant milestone in the antifungal drug discovery 
programs [53]. In comparison to its predecessor (polyenes), azoles are superior in terms of 
safety, efficacy, and oral bioavailability [57]. The azoles are broadly classified as imidazoles, 
which contain two nitrogens, and triazoles, which have three nitrogens on the azole ring [55]. 
Imidazoles are generally topical formulations, with an exception of ketoconazole 
administered systemically, for the treatment of mucosal and superficial fungal infections [55]. 
The structural modifications of ketoconazole led to discovery of four triazole molecules that 
are currently preferred antifungal drugs in the clinical setting: fluconazole, itraconazole, 
voriconazole, and posaconazole [57]. The mechanism of action of azoles are similar to that of 
polyenes in that they exert their pharmacological actions within the fungal cell membrane 
[53]. However, azoles inhibit cytochrome P (CYP) 450-dependent 14-α-demethylase 
(CYP51) resulting in inhibition of ergosterol formation leading to fungal cell membrane 
disruption and inhibition of growth [55]. This mechanism of action of azoles also results in 
cross-inhibition of some CYP-dependent enzymes in humans, which may contribute to 
toxicity profile seen in humans [52].  
1.2.3 Echinocandins 
Echinocandins are a recent class of antifungal drugs that are large lipopeptide molecules 
containing an amphiphilic cyclic hexapeptide with an N-linked acyl lipid side chain [57]. The 
first echinocandin to be approved by FDA was Caspofungin acetate that is synthesized from a 
fermentation byproduct of the filamentous fungus Glarea lozoyensis [53, 57]. Subsequently, 
Micafungin and Anidulafungin also were approved by FDA for various types of candidemia. 
Their mechanism of action involves inhibition of synthesis of β-(1,3)-D-glucan, an integral 
component of the fungal cell wall, thereby leading to weakened cell wall integrity and cell 
lysis [53, 57].  
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1.3 Genetic screens in C. albicans 
Functional fungal genome-wide studies facilitate identification of genes essential for the life 
of a fungal pathogen, which in turn define targets for antifungal drug discovery programs. For 
many decades S. cerevisiae has been an invaluable surrogate model to study the gene 
function in C. albicans [58]. However, unlike S. cerevisiae, C. albicans is a diploid 
polymorphic fungus without a full sexual life cycle [59]. These apparent differences have 
questioned the use of S. cerevisiae to study C. albicans biology [59].  
 
Completion of C. albicans genome sequencing project in 2004 marked a significant 
milestone in the functional analysis of the C. albicans genome. However, the use of 
molecular tool kits such as forward genetics has been challenging in this model organism as it 
lacks meiosis [59]. Despite these limitations, researchers have used various efficient gene 
disruption techniques to create C. albicans mutant libraries for studying C. albicans biology 
[59]. Figure 1 provides a brief comparison of the three commonly used mutant libraries of C. 
albicans [60-62]. Although, all these libraries are potentially a useful resource for both basic 
and applied studies, each of them have their own limitations [59] (See [63, 64] for reviews).  
1.4 Rationale 
As already noted, the nosocomial blood stream infections and candidemia caused by the 
opportunistic fungal pathogen, C. albicans, is a significant medical problem. Despite the high 
incidence and mortality rates in humans, relatively few efficacious antifungal drugs currently 
exist. Furthermore, the emergence of drug-resistant fungi and toxicity limit the clinical 
usefulness of these drugs. As a result, there is an urgent need for a new generation of 





Figure 1. A comparison of four largest mutant collections of C. albicans 
 
The completion human genome-sequencing project in 2001 marked the culmination of 
unprecedented advances in the science of genomics [65]. However, out of the vast majority of 
genes discovered, only a handful of them have been characterised [65]. Although the 
functional phenotype of each gene can be studied using classical genetics approaches, it is 
time consuming [65]. This situation has given rise to a new interdisciplinary field in science 
called "chemogenomics" - discussed in detail elsewhere [58, 65]. The use of chemogenomic 
profiling offers promise for characterizing the global cellular response to an arbitrary 
compound, for predicting the mode of action of a compound, and for inferring the function of 
genes [58]. The availability of the C. albicans deletion libraries such as gene replacement and 
conditional expression (GRACE) has enabled researchers to investigate the functional 













However, the requirement of tetracycline treatment to shut off gene expression is a significant 
limitation as the observed interactions may be consequence of the interaction of compound 
screened with tetracycline [61]. Hence, to avoid these potential false-positive findings, 
previous work in our laboratory involved construction of a derivative library (GRACE v1.0) 
from the GRACE collection to create a collection of non-conditional non-essential 
inactivated genes. Identification of C. albicans genes whose inactivation leads to either 
sensitivity or resistance of commercial antifungal drugs using GRACE v1.0 library could 
facilitate identification of drug targets for new anti-fungal agents.  
1.5 Objective and Aims 
1. To use the GRACE v1.0 library to study the interactions between specific anti-fungal drugs 
(fluconazole, posaconazole and amphotericin B) and a set of non-conditional mutants in non-
essential C. albicans genes.  
 
2. To characterise the utility of our modified version of GRACE library (GRACE v1.0) and 
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2. Materials and Methods 
2.1 Strains, Oligonucleotides and Plasmids 
The plasmids, strains, and oligonucleotides used are summarized in Table 1.  
Table 1. List of oligonucleotides, strains and plasmids 
 Oligonucleotides 
Experiment Oligo Sequence 5'-3' 

























X2-CaHIS1 CAACGAAATGGCCTCCCCTACCACAG  
X3-CaHIS1 GGACGAA TTGAAGAAAGCTGGTGCAACCG  
X2-CaARG4 AAT GGA TCA GTG GCA CCG GTG 















Strain Genotype Source 

















Collection of null, non-regulated non-essential 
genes 
 
Made by one of 
my lab member 
(Yuan) 
Plasmids 
S.No Plasmid Source 
1 pFA Arg4 [67] 
2 pFA His1 [67] 
*In the oligonucleotide sequence, capital letters represent those that are homologous to the 
NPY1 sequence in SN76 and the small letters represent sequences homologous to the plasmid. 
*Lowercase letters in LR182 primers represents the nucleotides necessary to attach the 
gRNA sequence into the plasmid by complementarity. Lowercase letters in LR183 primers 
indicates the changes in nucleotides compared with wild type sequence. These changes 
introduce stop codons; an enzyme restriction site and also they disrupt the PAM sequence.   
2.2 Drugs 
Fluconazole (FLU) and posaconazole (POSA) were purchased from Sigma-Aldrich, and 
Amphotericin B (AMB) was purchased from MP. For these studies FLU and POSA were 
dissolved in 99% ethanol and 99% methanol, respectively, and AMB was dissolved in 90 % 
dimethyl sulfoxide (DMSO). 
2.3 Growth Media 
Strains were grown in liquid mixture of 1% yeast extract, 2% peptone, 2% glucose and 
50mg/L uridine (YPD plus uridine; nutrient supplement) at 30°C, and the synthetic plates 
were supplemented with 100 mg/L of arginine, or histidine to allow optimal growth of his1- 




For screening purposes, 200µl liquid YPD with specific concentrations of each compound 
(discussed in later sections) was used. Liquid YPD was used for overnight cell cultures as 
well. Solid YPD plus uridine mixture was used for cell culture studies. For transformation 
experiments, solid synthetic complete –his or -arg was used. 
2.4 Compound screening in GRACE v1.0 library  
The GRACE (Gene Replacement and Conditional Expression) library represents 
approximately 2500 strains that include regulated expression constructs for both essential as 
well as non-essential genes. Much of the work in the literature has been focused on the role of 
essential genes. Hence, to characterize the role of non-essential C. albicans genes, a modified 
version of GRACE library (GRACE v1.0) was designed previously in our laboratory. 
Additionally, unlike the conditional mutants, these non-conditional mutants do not require the 
addition of tetracycline. This in turn prevents any potential drug-drug interactions that may 
occur otherwise. 
2.4.1 Experiment One 
A total of 887 non-essential mutants of C. albicans from GRACE (gene replacement and 
conditional expression) v1.0 (Appendix; Table A1) library collection were organized in 96-
well microtiter plates. Briefly, approximately 2 µl of the each strain of cells from saturated 
cultures were transferred to fresh 200 µl of YPD with uridine using a replicator‐pinning tool. 
Then, the same tool was used to transfer approximately 2 µl samples of cells from the 
intermediate dilution in YPD to 200 µl fresh YPD without drug to function as controls. 
Similarly, 2 µl samples of cells were transferred from the intermediate dilution of YPD to 
200µl fresh YPD media with known concentrations of each drug (Figure 2). The 
concentration of FLU and POSA used in this study were 10 and 0.1 µg/ml, respectively, and 
that of AMB was 1 µg/ml. These initial drug concentrations were selected to allow saturated 
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growth of the control strains after 3 days, while drug free controls showed saturated growth in 
less than 2 days. Each well had an approximately 10-4 dilution of the saturated culture to 
provide the starting density. The plates were then incubated at 30°C for five days (Figure 3).  
If a strain showed saturated growth before 3 days in the presence of the drug it was classified 
as resistant. If a strain failed to grow or showed saturation of growth after 5 days, it was 
called as sensitive. Each experiment was repeated at least 3 times. The growth was quantified 
by Tecan Sunrise machine. A semi‐quantitative scoring scale represented the day that 
saturation growth was observed. A score of 1 and 2 represented resistance, and 5 and 6 
represented sensitivity.  
2.4.2 Experiment Two 
Strains that showed consistent sensitivity in all 3 replicates for both FLU and POSA were 
then tested again using different concentrations of the drug; FLU (10 μg/ml, 7 μg/ml and 3 
μg/ml) and POSA (0.1 μg/ml, 0.07 μg/ml and 0.03 μg/ml). Similarly, the strains that were 
consistently resistant to both drugs were once again tested at different concentrations of FLU 
(10 μg/ml , 15 μg/ml and 20 μg/ml) and POSA (0.1 μg/ml, 0.15 μg/ml and 0.20 μg/ml). 
Subsequently, 5 of the most sensitive and resistant strains were chosen from the highly 
sensitive and resistant strains and their growth curves were measured in presence of FLU 
(3 μg/ml) and POSA (0.03 μg/ml) and these strains were designated super-sensitive or super-
resistant. Likewise, strains that showed consistent sensitivity to AMB were tested again using 
different concentrations of the drug, viz. 1 μg/ml, 0.7 μg/ml and 0.3 μg/ml, and 5 of the most 
sensitive strains were randomly chosen from the most sensitive strains and their growth 
curves were measured in presence of 0.3 μg/ml of AMB.  
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Figure 3. Screening of GRACE v1.0 in 96 well plates for five days to select sensitive and 




2.5 Comparison of sensitive and resistant strains in GRACE vs 
GRACE v1.0 library   
On completion of Experiment Two, the top 5 sensitive and resistant strains were chosen for 
comparison. Because of the appearance of unrelated loss of heterozygosity events in a subset 
of the GRACE v1.0 library, candidates of the sensitive and resistant classes for each drug 
were tested with the original GRACE strain under tetracycline inactivation. The protocol 
used for this study as well as the doses for FLU, POSA and AMB were similar to that of 
Experiment One (Section 2.4.1).  
2.6 Construction and validation of SN76 NPY1 strain 
2.6.1 Plasmid extraction 
Escherichia coli strain DH5alpha was used for plasmid amplification. Lysogeny Broth (LB) 
media was prepared and supplemented with 100 µg/mL Ampicillin (LB plus Amp) after 
autoclaving and cooling the agar to 55°C. The strains of E. coli were then streaked onto 
media and incubated overnight at 37°C. The following day, single colonies of E. coli were 
cultured in 5ml of LB plus Amp overnight at 37C, and were stored in 4°C until further use. 
The following day, plasmid DNA was extracted using QIAprep Spin Miniprep Kit (Qiagen) 
as per manufacturer's protocol. However, in the final step of extraction, the plasmid DNA 
was eluted in sterile distilled water instead of EB buffer provided along with the kit.  
2.6.2 PCR amplification of deletion cassette 
A 500-μL reaction mixture, with appropriate 120bp foreword primer-S1 (100 bp are 
homologous of the NPY1 (NAD(+) diphosphatase) sequence in SN76 and S1 is homologous 
of the plasmid as well for 120bp reverse primer-S2 (mentioned in Table 1). The size of pFA-
ARG4 plasmid is 2017bp. The mixture for PCR was made in a 1.5 mL sterile tube, and is 
summarised in Table 2. I expected the size of the band 2257bp. pFA means backbone of the 
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plasmid and it is similar in all other plasmid like pFA-HIS1 this allowed the “open” 
construction of pFA-modules for Candida albicans in which single components can easily be 
exchanged for new ones upon availability  [67].  
 
The thermal cycling parameters for PCR are as follows:  
 Denaturation at 98°C for 2 min 
 25 Cycles of 98°C for 30 sec and annealing/extension at 55°C for 30 sec. 
 Final extension at 72°C for 10 min* 
*If the sample was to be left overnight in the machine, a final step at 4°C for unlimited time 
was added to the program to prevent degradation of the samples. 
In order to confirm the amplification of the desired template, the final PCR products were run 
on a 1% agarose gel to confirm the size of the final product.  
 
Table 2. PCR reaction mix for amplification of deletion cassette 
REAGENT For 50 μL reaction For 500 μL reaction 
Q5 Buffer (New England Bio labs) 10 100 
Sterile distilled water 31.5 315 
10 mM dNTPs 2 20 
10 μL Forward primer (10nM) 2 20 
10 μL Reverse primer (10nM) 2 20 
Plasmid (diluted 1:20; 100 µg/ml) 2 20 
Q5 enzyme (New England Bio labs) 0.5 5 
2.6.3 Precipitation of DNA 
On confirmation of the amplification of the desired template, 495 µl of each PCR product 
was mixed with 1/10 volume of 3 M sodium acetate (pH 5.3). To precipitate the DNA with 
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ethanol, the sample was then mixed with 2X volume of 99% ethanol and gently shaken for 5 - 
10 min. The samples were then precipitated overnight at -80°C. The following day, the 
samples were centrifuged at 4°C for 30 min (14000 rpm). The supernatant was discarded and 
the DNA pellet was washed in 70% ethanol and re-centrifuged. The washed pellet was then 
air dried and re-suspended in 100 µl of sterile distilled water. The DNA was quantified using 
a nanospec instrument.  
2.6.4 Strain Transformation 
The SN76 C. albicans strain was grown in a Falcon tube with 5mL of YPD at 30°C overnight 
with shaking. The following day, 200 µl of the overnight culture was centrifuged (30 sec @ 
9000 rpm) and the pellet was washed using 200 µL of 1 M lithium acetate in Tris- EDTA 
(TE) to permeablize the cell wall of Candida albicans to permit DNA transformation. After 
re-centrifugation, the pellet was re-suspended in 100 µL of freshly prepared ice cold one-step 
buffer (1 mL of buffer contains 200 µL of 1 M lithium acetate in TE and 800 µL of 55 % w/v 
PEG (polyethylene glycol), 15 mg DTT (DL-Dithiothreitol), 25 µL single-stranded salmon 
sperm DNA). Next, 10 µl of precipitated DNA (@ 2, 6 and 10 µg) collected from Section 
2.6.3 was added and the transformation mixture was incubated at 30°C for 1h to overnight on 
a shaker. The mixture was then incubated at 44 °C for 15 – 30 min and cells were plated onto 
solid synthetic complete media (SC) plus uridine plates without arginine and incubated for at 
least 3 days at 30°C. Single colonies of the transformed strain were then isolated and streaked 
onto separate plates with the same media (SC plus uridine without arginine) and incubated at 
30°C. A colony PCR with a reaction mixture (summarized in Table 3) and primer (X2-
CaARG4which is 20 bp of ARG4 plasmid was used as reverse primer and NPY1-exF, which 
is 20 bp of NPY1 was used as a forward primer, or X3-CaARG4 and NPY1-exR; summarized 
in Table 1) was performed to confirm the knockout of one of the alleles of the NPY1 gene 
(the NPY1 gene has two alleles) as shown in figure 4 B [67]. The thermal cycling parameters 
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used were: 94°C for 3min, 25 cycles of 94°C for 30 sec, 51°C for 1 mins, 72°C for 3 mins, 
and 72°C for 10min. After confirmation of the first knockout allele with ARG4 cassette, 
strains heterozygous at NPY1 were taken to transfer the second allele with the His1 cassette. I 
PCR amplified the His1 cassette (his1 cassette size is 1429 bp) with flanking sequences and 
transform C. albicans followed by selecting His+ transformants and confirmed deletion of the 
second allele of NPY1 by doing colony PCR as shown in figure 4(C).  Then I confirmed that 
the his+ insertion has not replaced the arg+ insertion allele, and also there is no sequence of 
NPY1 left in the genome by colony PCR using ether primers: X2- CaHIS1 and NPY1-exF or 
X3- CaHIS1 and NPY1-exR; summarized in Table 1).  
 
Table 3. Reaction mixture for transformed strain PCR 
REAGENT For 50 μL reaction 
10 x Taq Buffer 5 
Sterile distilled water 38 
50 mM MgCl2 1.5 
10 mM dNTPs 1 
10 μL Forward primer 1 
10 μL Reverse primer 1 
Strain (diluted 1:20) 2 





 Figure 4: NPY1 Transformation. 
(A) Amplification of pFA-ARG4 deletion cassette for disruption of the first allele of NPY1 with 
120bp foreword primer-S1and 120bp reverse primer-S2 and 2.017bp of ARG4 sequence from 
the pFA-ARG4 plasmid. This generates an expected band size of 2257bp. 
(B) To confirm the first knockout, a colony PCR with a reaction mixture primers (X2-
CaARG4 which is 20 bp internal to the ARG4 gene was used as reverse primer and 20 bp of 























Figure 4: NPY1 Transformation. 
(C) Amplification of pFA-HIS1 cassette for disruption of the second allele of NPY1 .120bp 
foreword primer-S1, 120bp reverse primer-S2, and 1429 bp of HIS1 from the pFA-HIS1 
plasmid. This generates an expected band of 1669 bp. 
(D) To confirm the second knockout, a colony PCR with a reaction mixture primers (20 bp 
X2-CaHIS1 of HIS1 gene used as foreword primer and 20 bp of the flanking sequence of 























Figure 4: NPY1 Transformation. 
(E) Conformation NPY1 Transformation with SN76 using 20 bp primers upstream and 
downstream in the flanking sequence of NPY1. Expecting one band of 1632 bp.  
(F) Conformation NPY1 Transformation generating heterozygous NPY1 using 20 bp up and 
down of the flanking sequence of NPY1.  Expecting two bands,(1632 bp (SN76) and 2257bp 
(ARG4)).  
(G) Conformation NPY1 Transformation generating homozygous npy1 using 20 bp up and 
































































Figure 4: NPY1 Transformation. 



































2.7 Construction of SN148 PAA11 strain 
The SN148 PAA11 (Potential polyamine N-acetyl transferase) strain was constructed using 
CRISPR, as previously documented [68]. Briefly, phosphorylated and annealed PAA11 guide 
RNA primers (LR182F and LR182R; Table 1) were ligated to CIP-treated BsmBI-digested 
pV1093 vector. Mutagenic double stranded oligonucleotide (LR183F and 183R) was used as 
a repair DNA. This oligonucleotide is complementary to PAA11 and contains a mutation on 
PAM sequence, two premature stop codons (UAA, UAG) and a HindIII restriction site. 
Standard LiAc transformation was done on the SN148 strain. Transformants obtained on 
YPD Nat plates were screened by PCR using the primers LR184F and LR184R followed by 
HindIII digestion. Correct clones were verified by sequencing. 
2.8 Bioinformatics analyses 
To analyse different genes within a class, I used a Venn diagram program 
(http://www.bioinformatics.lu/venn.php). The ortholog comparisons among fungal species 









































3.1 Compound screening in GRACE v1.0 library 
3.1.1 Experiment One: Azoles 
Among 887 non-essential mutants of C. albicans from the GRACE v1.0 library, 119 strains 
were resistant and 81 strains were sensitive to FLU (10 µg/ml). Testing of POSA (0.1 µg/ml) 
showed 101 resistant and 145 sensitive strains. Both compounds gave clear sensitivity and 
resistance profiles, and the overlap between the two different azole compounds was 
considerable (Figure 5A and B). The list of strains that were resistant and sensitive to FLU, 
POSA and both compounds are tabulated in Table A2, A3 and A4, respectively. 
 
 
Figure 5. Comparisons of genes showing sensitivity or resistance to two azoles, FLU and 
POSA. A) 43 strains showed a common resistance to both FLU and POSA. B) 49 strains 
showed a common sensitivity to both FLU and POSA. 
 
3.1.2 Experiment One: AMB 
In contrast, among 887 non-essential mutants of C. albicans from the GRACE v1.0 library, 




3.1.3 Experiment Two: Azoles 
A set of 37 strains out of the 49 consistently sensitive strains was then tested at diminishing 
concentrations of both FLU (10 μg/ml, 7 μg/ml and 3 μg/ml) and POSA (0.1 μg/ml , 0.07 
μg/ml and 0.03 μg/ml). Likewise, 37 resistant strains out of the 43 commonly resistant strains 
were tested with increasing concentrations of FLU (10 μg/ml, 15 μg/ml and 20 μg/ml) and 
POSA (0.1 μg/ml , 0.15 μg/ml and 0.2 μg/ml). Table 4 summarizes the five of the most 
sensitive and resistant strains to both FLU and POSA. The growth curves measured by Tecan 
machine for the 5 super resistant, and 5 super sensitive strains to azoles are shown in Figure 
6A and B. The comparative growth curves of the super sensitive and resistant strains and 
cass1 WT strain in the presence of FLU and POSA over 5 day period are shown in Figure 7, 
8, 9 and 10.  
 
Table 4. Strains showing super-sensitivity or super-resistance to both FLU and 
POSA. 
Super Sensitive Strains Super Resistant Strains 
Orf name Gene name Orf name Gene name 
orf19.2557 SEC65 orf19.767 ERG3 
orf19.3482 NPY1 orf19.6199 HCS1 
orf19.4631 ERG251 orf19.260 CaORF6_1455 
orf19.7269 PAA11 orf19.1773 RAP1 






Figure 6. The growth curves of super resistant and super sensitive strains in presence of 






Figure 7. Growth curves of the sensitive C. albicans strains and cass1 WT strain in presence 





































































































































































Figure 8. Growth curves of the resistant C. albicans strains and cass1 WT strain in presence 










































































































Figure 9. Growth curves of the super sensitive C. albicans strains and cass1 WT strain in 












































































Figure 10. Growth curves of the super resistant C. albicans strains and cass1 WT strain in 





































































































































































3.1.4 Experiment Two: AMB 
Figure 11 summarizes the growth curves of 5 of the super sensitive strains in the absence and 
presence of AMB at 1µg/ml. Table 5 summarizes the five of the most sensitive strains to 
AMB. Growth curves of the super sensitive strains and cass1 WT strain in presence of AMB 
over 5 days (0.7µg/ml and 1µg/ml) or 8 days (1µg/ml) are shown in Figure 12.  
 
 
Table 5. Strains showing super-sensitivity to AMB. 
Super Sensitive Strains 




































































































































































































Figure 12. Growth curves of the super sensitive strains and cass1 WT strain in presence of 
AMB (A) 1µg/ml, WT is red color and (B) 0.7µg/ml over 5 days, WT is red color, and (C) 1µg 
/ml over 8 days. 
3.2 Comparison: GRACE v1.0 vs GRACE library   
3.2.1 Azoles 
Figure 13 shows the growth profile of the five of the super sensitive and resistant strains in 
GRACE and GRACE v1.0 library, in the absence of drug. The results for the 5 strains that 
were resistant to azoles (both FLU and POSA) when tested in GRACE v1.0 library were also 
resistant when tested in the GRACE library where strains were inactivated by tetracycline. In 
contrast, 3 out of the 5 strains (null mutants for NPY1, PAA11, and SOG2) that are sensitive 
to FLU and POSA in GRACE v1.0 library were shown to not be sensitive when tested in the 























Figure 13. Growth curves of five super sensitive and resistant strains in (A) GRACE and (B) 




Figure 14. Comparison of five strains that are super sensitive and super resistant to FLU 
and POSA in GRACE v1.0 library and GRACE library inactivated by tetracycline. Dotted red 
box indicates the differences in sensitivity/resistance profiles between GRACE v1.0 and 





Consistent with the results of GRACE v1.0 library, the 5 strains that were super sensitive to 
AMB were also sensitive when tested in GRACE library (Figure 15). 
 
 
Figure 15. Comparison of five strains that are super sensitive to AMB in GRACE v1.0 library 
and GRACE library inactivated by tetracycline. 
3.3 Screening of Azoles in SN76 NPY1 mutant and SN148 PAA11 
mutant strains 
3.3.1 NPY1 mutant SN76 strain 
The knockout of NPY1 gene in both the alleles of SN76 C. albicans strain was confirmed 
using colony PCR for the Arg marker (Figure 4A) and the His marker (Figure 4B). The 
testing of NPY1 mutant SN76 strain with 10 µg/ml FLU (Figure 16A) and 0.1 µg/ml POSA 
(Figure 16B) over 5 day period showed sensitivity profile for both azoles c.f. SN76 WT. 







Figure 16. Growth curves showing sensitive profiles for SN76 NPY1 mutant strain in the 
presence of (A) 10 µg/ml FLU and (B) 0.1 µg/ml POSA c.f. WT SN76 strain. 
3.3.2 PAA11 mutant SN148 strain 
The PAA11 mutant SN148 strain generated using CRISPR and the respective WT SN148 
strain were tested in the presence of 10 µg/ml FLU (Figure 17A) and 0.1 µg/ml POSA 
(Figure 17B) over a 5 day period. My findings showed that the PAA11 mutant SN148 strain 
was sensitive to both FLU and POSA c.f. SN148 WT strain, as seen in GRACE v1.0 library,  
 
 
Figure 17. Growth curves showing sensitive profiles for SN148 PAA11 mutant strain in the 
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In the present study, I screened an in-house derived collection of approximately 900 non-
essential, transactivator-defective disruption Candida albicans strains (GRACE v1.0 library) 
against classic anti-fungal drugs to identify genes that confer either enhanced sensitivity or 
increased resistance. Specifically, I examined the effects of two azoles, fluconazole (FLU) 
and posoconazole (POSA), as well as the polyene, amphotericin B (AMB). Overall, the 
chemogenomic profiles suggest that different drug classes interact with discrete networks of 
C. albicans genes.  
 
To date, Candida spp., most notably C. albicans, has been known to cause a substantial 
fraction of human fungal disease [3]. These fungal pathogens are the third most common 
cause of nosocomial infections in the global adult, [77] as well as pediatric, populations [78]. 
The major classes of antifungal drugs include polyenes, azoles, and echinocandins [29,43,48]. 
However, poor efficacy and/or dose-limiting side effects limit the existing antifungal agents. 
Futhermore, there is an increase in the growth of populations of drug resistant strains [3]. 
Hence, there is a great need to better understand the signalling and/or regulatory pathways 
that confers sensitivity and/or resistance to a given class of antifungal agent in this fungal 
pathogen. 
 
The completion of C. albicans genome sequencing project in 2004 gave rise to various 
molecular tool kits, including various C. albicans mutant libraries [27,57]. These libraries 
have served as invaluable tools to investigate the genes that confer resistance or sensitivity to 
antifungal drugs and to study the pathobiology of this model organism [27,57]. Among these 
libraries, the gene replacement and conditional expression (GRACE) set has been widely 
used to study various C. albicans functions. However, a significant limitation of this 
approach includes the use of tetracycline, which may potentially interact with the compound 
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used or the process investigated in the study [56]. Hence, a modified version of this library 
involving a collection of non-conditional non-essential inactivated genes was recently 
constructed and validated in our laboratory, and was used for the experiments herein.  
 
In the present study, first I screened the 887 non-essential mutant C. albicans strains from 
GRACE v1.0 library in the presence of commercially available azole antifungal drugs 
fluconazole (FLU) and posaconazole (POSA). Among the 887 mutant strains, 49 and 43 
strains were found to be sensitive and resistant, respectively, to both FLU and POSA (see 
Table A4). Next, 37 strains that were both sensitive (or resistant) to FLU and POSA were 
randomly chosen and were screened again using various concentrations of the azole drugs. 
The top 5 strains that were sensitive (SEC65, ERG251, NPY1, PAA11 and SOG2 mutants) 
and resistant (ERG3, HCS1, CaORF6_1455, RAP1, ADP1 mutants) to both FLU and POSA 
were chosen for subsequent studies. A brief description of the role of these genes has been 
summarized in Table 6.  
 
My findings for SOG2 and ERG3 are consistent with that of reported previously [60,64]. 
However, the functions of the other genes remain uncharacterized in C. albicans. 
Additionally, my findings showing that ERG3 mutant strain was resistant to azole, but 
sensitive to AMB, further implies that different classes of drugs targeting the same 
biosynthetic pathway also may have different chemogenomic profile. Although, the function 
of RAP1 has been characterized in C. glabrata [16] and S. cerevisiae [59], comparison of 
genetic disruptions conferring drug sensitivity in other fungi should be carefully done. In 
order to compare the genomic profile for azole sensitivity among different fungi, datasets of 
azole sensitive S. cerevisae and C. glabrata strains from previously published large-scale 
chemogenomic profiling studies were collected [45,62,65]. Since there were two large-scale 
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studies involving S. cerevisae [45,65], first I determined the common set of azole sensitive 
genes in S. cerevisae using the Venn diagram program 
(http://www.bioinformatics.lu/venn.php). My analysis revealed that out of 330 and 403 azole-
sensitive genes from Dr. Boone’s lab [45] and Dr. Tyers lab [65], respectively, only 91 genes 
overlapped (Appendix A8). The dataset generated was further compared with that of the 14 
azole sensitive C. glabrata strains from Dr. Kuchler lab [62] (Appendix A10) and the 49 
azole sensitive C. albicans strains from my study (Appendix A9) using the Venn diagram 
program. Interestingly, the comparison of the genomic profile for azole sensitivity among 
different fungi showed no common genes (Figure 18). Hence, this suggests that the 
chemogenomic profile of a given antifungal azole drug can differ significantly among 
organisms even when the apparent target of the drug is the same [62,65]. Furthermore, as 
shown in Figure 18, the number of strains that are sensitive to azoles in S. cerevisiae is much 
higher than the other fungal organisms suggesting that azoles affects numerous signalling 
pathways in S. cerevisiae. In support of this notion, recent work by Epp and colleagues 
involving screening of S. cerevisiae to identify synergistic drug interactions that render FLU 
fungicidal and validation of the same in C. albicans showed that out of 22 predicted genes in 
S.cerevisiae only one gene mediated FLU tolerance in C. albicans [19]. 
 
Of specific interest, null mutants of two genes involved in the ergosterol biosynthetic 
pathway, ERG3 and ERG251/ERG25, seem to result in resistant and sensitive profiles, 
respectively, to azoles. There is still some confusion as to how to address why deletion of 
ERG3 causes resistance to azoles and ERG251/ERG25 causes sensitivity. ERG3 encodes the 
∆5, 6 desaturase (also known as Erg3p), an enzyme that acts late in the ergosterol 
biosynthesis pathway [2]. Erg3p is responsible for converting tolerated 14-methyl 
intermediates, which accumulate because of azole inhibition of the 14C-lanosterol 
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demethylase, into the toxic sterol 14-methylergosta-8,24(28)-dien-3,6-diol [2]. Therefore, 
ERG3 inactivation should and does confer azole resistance. Or in other words, ERG3 destroys 
a beneficial compound and replaces it with a toxic variant if active, in the presence of azoles, 
so the absence of Erg3p prevents the beneficial compound from being destroyed and keeps 
the cells living and thereby makes them resistant to azoles. The explanation of ERG251/25 is 
more complicated. In S. cerevisiae, ERG25 deletion confers resistance to cells in presence of 
azoles [2]. In Candida biofilms, ERG25 expression is upregulated by the presence of azoles in 
general and fluconazole in particular [40]. The difference in biofilms in comparison to the 
yeast is that growth happens in anaerobic conditions in the former. This could be one reason 
why the expression of ERG251/25 increases in this case. However others like Boreca-
Melkusova and colleagues [10] have shown that while expression of ERG25 increases in 
Candida dubliniensis biofilms on fluconazole exposure, the same is not observed in Candida 
albicans. The reason they give for this is strain specificity. The detailed mechanism 
underpinning these observations remains for future investigation. 
 
Next, I screened 887 non-essential mutant C. albicans strains from GRACE v1.0 library in 
the presence of AMB. My findings showed that 268 strains were sensitive to AMB (Table 
A5) and that no strains from the GRACE v1.0 library were resistant. My finding of no AMB 
resistant strains is intriguing and previous studies have also failed to show good candidates 
for AMB resistance. It has been speculated that AMB-induced accumulation of reactive 
oxygen species could possibly explain the low rate of resistance to AMB [34]. However, the 
molecular mechanisms underlying this phenomenon are unclear. Similar to comparison of 
genome profile of azole sensitivity, the genome profile for AMB sensitivity was compared 
using dataset generated from my study in C. albicans and from previously published papers 
in S. cerevisiae and C. glabrata (Figure 19). My analysis showed that out of 273 AMB 
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sensitive genes in S. cerevisiae (Appendix A7) [45], 268 genes in C. albicans (Appendix A6) 
and 13 genes in C. glabrata (Appendix A10) [62], only one common gene (SAC7; Putative 
GTPase activating protein for Rho1) was involved, further implying the same as observed in 
azole sensitivity among different fungal pathogens.  
 
Subsequently, the top 5 of the sensitive strains (PCM1, PDS5, RPO21, MNR2 and YAK1 
mutants) were chosen and were screened again using various concentrations of AMB. A brief 
description of the role of these genes has been summarized in Table 6. To the best of my 
knowledge, this is the first study that has demonstrated the sensitivity profile for the 
aforementioned mutant strains to AMB.  
 
Following the selection of the top 5 super-sensitive and super-resistant strains to FLU, POSA 
and/or AMB using GRACE v1.0 library, I then screened the same mutant strains from 
tetracycline-inactivated parent GRACE library. This was undertaken to ensure that there were 
no differences in the sensitivity or resistant profiles for a given drug when screened using 
GRACE v1.0 and the parent GRACE library. My findings showed that the 
sensitivity/resistant profiles for the 5 strains from GRACE library that were super-resistant to 
azoles (FLU and POSA) and super sensitive to AMB were similar to that observed in 
GRACE v1.0 library. However, 3 out of the 5 strains (null mutants for NPY1, PAA11, and 
SOG2) that were super sensitive to FLU and POSA in GRACE v1.0 library were found to be 







Table 6. Description of genes those are sensitive and/or resistant to FLU, POSA 


































































Previous work by others using C. albicans strain knockout experiments have demonstrated 
the sensitive profile for SOG2 mutants in the presence of azoles similar to that observed in 
GRACE v1.0 library [64]. Hence, in order to understand the apparent differences in the 
profile of supersensitive NPY1 and PAA11 strains in GRACE and GRACE v1.0, I then 
constructed null mutants for NPY1 and PAA11 (CRISPR allele was obtained from a 
colleague) using the SN76 and SN148 C. albicans strains. My findings showed that the NPY1 
and PAA11 mutant strains were indeed sensitive to FLU and POSA, validating my findings in 
GRACE v1.0 library. This in turn corroborates the utility of GRACE v1.0 library and 
supports my hypothesis that screening of compounds in GRACE parent library may result in 
false positive findings possibly due to interaction with tetracycline. 
 
In conclusion, screening an in-house derived collection of approximately 900 non-essential, 
transactivator-defective disruption Candida albicans strains against classic anti-fungal drugs 
demonstrated genes that confer either enhanced sensitivity and resistance to azoles and AMB. 
An important limitation of the current study is that only 5 of the most super sensitive and 
super resistant strains in each anti-fungal drug class were investigated in detail. Future studies 
to better understand other genes that confer sensitivity and resistance to azoles and AMB are 
warranted. Furthermore, the present study also has characterized the utility of using GRACE 
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APPENDIX A4: Strains resistant and sensitive to both 











































































































































APPENDIX A5: Strains sensitive to AMB in C. albicans 
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Strains sensitive to AMB 
orf19.665 orf19.5720 orf19.52 orf19.6020 orf19.895 
orf19.5013 orf19.1719 orf19.1236 orf19.1159 orf19.3100 
orf19.1387 orf19.6195 orf19.212 orf19.5496 orf19.7512 
orf19.6860 orf19.2484 orf19.6877 orf19.2411 orf19.1042 
orf19.2835 orf19.2008 orf19.4240 orf19.1449 orf19.5043 
orf19.1295 orf19.5658 orf19.6727 orf19.234 orf19.5728 
orf19.7136 orf19.744 orf19.1130 orf19.6167 orf19.4658 
orf19.3366 orf19.3542 orf19.5849 orf19.1832 orf19.4831 
orf19.6025 orf19.299 orf19.2423 orf19.5789 orf19.5090 
orf19.2216 orf19.2092 orf19.991 orf19.6464 orf19.1989 
orf19.7413 orf19.2073 orf19.4546 orf19.2882 orf19.4764 
orf19.4005 orf19.3822 orf19.4287 orf19.4229 orf19.287 
orf19.5379 orf19.3841 orf19.5592 orf19.6592 orf19.3152 
orf19.6422 orf19.6558 orf19.3929 orf19.841 orf19.1857 
orf19.7363 orf19.6533 orf19.6398 orf19.3586 orf19.147 
orf19.4336 orf19.5263 orf19.2151 orf19.4519 orf19.7355 
orf19.7655 orf19.2251 orf19.7158 orf19.478 orf19.4112 
orf19.4015 orf19.2031 orf19.857 orf19.1394 orf19.4981 
orf19.6294 orf19.6237 orf19.5780 orf19.3980 orf19.4906 
orf19.4258 orf19.6011 orf19.5859 orf19.1659 orf19.2990 
orf19.5148 orf19.2425 orf19.4688 orf19.7324 orf19.4316 
orf19.6640 orf19.6287 orf19.1663 orf19.1078 orf19.5411 
orf19.4697 orf19.7390 orf19.105 orf19.4339 orf19.2514 
orf19.2761 orf19.3482 orf19.183 orf19.5667 orf19.4372 
orf19.4635 orf19.6152 orf19.1946 orf19.517 orf19.728 
orf19.3058 orf19.4446 orf19.835 orf19.5530 orf19.916 
orf19.6075 orf19.6928 orf19.2798 orf19.2114 orf19.7337 
orf19.1232 orf19.7218 orf19.4376 orf19.5784 orf19.5393 
orf19.5895 orf19.5673 orf19.7629 orf19.4325 orf19.723 
orf19.6707 orf19.4186 orf19.4560 orf19.2772 orf19.5827 
orf19.6168 orf19.5495 orf19.1698 orf19.2792 orf19.7440 
orf19.2666 orf19.1235 orf19.3705 orf19.5295 orf19.2618 
orf19.4128 orf19.6766 orf19.2945 orf19.2467 orf19.7115 
orf19.1891 orf19.2703 orf19.5103 orf19.4804 orf19.5729 
orf19.3298 orf19.4475 orf19.3458 orf19.604 orf19.1887 
orf19.350 orf19.2007 orf19.5071 orf19.2553 orf19.2926 
orf19.897 orf19.313 orf19.4783 orf19.2248 orf19.7668 
orf19.4845 orf19.3649 orf19.23 orf19.6059 orf19.4772 
orf19.6981 orf19.5869 orf19.1160 orf19.4950 orf19.3804 
orf19.3035 orf19.3558 orf19.5662 orf19.4593 orf19.1419 
orf19.7156 orf19.403 orf19.2942 orf19.732 orf19.500 
 84 
 
Strains sensitive to AMB 
orf19.2790 orf19.3432 orf19.2312 orf19.2952 orf19.7322 
orf19.1066 orf19.3679 orf19.6344 orf19.669 orf19.5029 
orf19.300 orf19.4175 orf19.2988 orf19.6992 orf19.3232 
orf19.1062 orf19.6653 orf19.4381 orf19.3267 orf19.7565 
orf19.782 orf19.26 orf19.3122 orf19.2077 orf19.7619 
orf19.3912 orf19.6606 orf19.3106 orf19.6847 orf19.7666 
orf19.4668 orf19.6271 orf19.5838 orf19.1124 orf19.5919 
orf19.5611 orf19.4943 orf19.1421 orf19.7490 orf19.3995 
orf19.3308 orf19.4197 orf19.4579 orf19.4624 orf19.1723 
orf19.3219 orf19.3222 orf19.843 orf19.240 orf19.698 
orf19.387 orf19.3412 orf19.5102 orf19.5534 orf19.3243 
orf19.3445 orf19.3065 orf19.7320 orf19.4119  




























APPENDIX A6: Systemic Name of sensitive Strains to 
AMB in C. albicans
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Strains sensitive to 
AMB 
YKR088C YER164W YGL100W 
YMR077C YDR126W YKL209C YPR173C 
YLR106C YGR208W YDR264C YLR306W 
YIL067C YJL141C YNL323W YOR067C 
YMR177W YPL067C YDL167C YER052C 
YLR027C YOR137C YPL065W YEL058W 
YNL277W YMR137C YGL184C YIL124W 
YHR005C YMR027W YOR165W YCR090C 
YBL021C YNL141W YEL019C YCR036W 
YKL041W YGL047W YPR201W YDR261C 
YNL305C YGR255C YDL244W YGR271W 
YJR123W YGR276C YGL180W YGR094W 
YBR005W YBR290W YJL156C YPL030W 
YPR113W YOL138C YDR483W YBR239C 
YDL140C YLR120C YIR004W YPL096W 
YIL003W YPL265W YFL013C YMR241W 
YDR335W YGR116W YER040W YNL055C 
YPL029W YGL094C YPR184W YPR127W 
YPL167C YDR408C YHR168W YBR126C 
YMR309C YPR088C YOR129C YGL225W 
YDR061W YHR178W YLL012W YJR093C 
YMR099C YDL018C YER081W YDR415C 
YOL004W YER167W YMR125W YFL030W 
YGL124C YMR154C YGR135W YBR086C 
YGR217W YBR101C YCR079W YKR051W 
YPL230W YPL133C YGR287C YBR115C 
YIR028W YMR071C YPR180W YHR181W 
YGR284C YNL175C YLR300W YNL073W 
YNL094W YEL023C YOR163W YOR198C 
YMR283C YNL180C YKR013W YDR338C 
YJL005W YMR134W YOL018C YNL316C 
YNL242W YPL190C YDR513W YNL062C 
YPL116W YLR113W YMR055C YHR132C 
YJR142W YLR186W YGL186C YER118C 
YGR125W YJL055W YPR118W YDR302W 
YMR076C YNL217W YNL200C YPL225W 
YIL099W YKL046C YIL090W YOL129W 
YOL151W YPL154C YCR068W YDR332W 
YBR199W YIR032C YJR100C YKR065C 
YBR204C YGL067W YDL178W YKL179C 
YJR075W YIL041W YPR167C YDL127W 
YDR379W YMR171C YDR027C YLR316C 
YDR245W YJL093C YNR019W YOR202W 
YNL279W YKL018W YNR007C YHR035W 























































Strains sensitive to AMB 










Systemic Name YLR039C YDR392W YER092W 
YDR276C YPL057C YIL056W YOR067C 
YDR326C YGR197C YPR051W YIL111W 
YNL257C YDR310C YAL012W YIL092W 
YJR118C YLR200W YGR252W YHR168W 
YHR155W YNL015W YJR059W YPR124W 
YMR102C YGL020C YBR041W YEL062W 
YDR207C YDR418W YBR168W YBL042C 
YLR372W YKL081W YAL056W YHL006C 
YJL056C YNR029C YNL190W YLR090W 
YLR182W YDR297W YNR031C YIL161W 
YLR315W YGL035C YHL043W YCR045C 
YPL105C YGR122W YDL232W YBR021W 
YNL041C YJL139C YAL013W YDR293C 
YOR008C YJL183W YDR530C YMR185W 
YMR109W YDR484W YJL128C YDR071C 
YDR497C YGR143W YNR075W YOL103W 
YBL086C YMR060C YBL067C YNL197C 
YBR126C YPR095C YJR152W YNL099C 
YPR097W YJR139C YMR216C YCR019W 
YGR285C YPL056C YHR100C YIL116W 
YGL253W YLR110C YFL001W YGL066W 
YKR028W YER110C YMR038C YNR001C 
YGR229C YOR371C YHL028W YDR028C 
YIR033W YBR200W YNL051W YOR109W 
YBL072C YPR040W YIL073C YPR139C 
YNL307C YMR264W YML074C YLR006C 
YKL037W YJL198W YHL047C YHL040C 
YER048C YDR389W YIL077C YKL216W 
YGL005C YNL323W YGL167C YCR017C 
YLR418C YGL062W YPL262W YBR295W 
YDR072C YLR113W YIL042C YPL214C 
YLR262C YGL219C YIR016W YGL252C 
YOR035C YML123C YNL259C YMR283C 
YLR454W YDL002C YDR448W YNL154C 
YDR320C YIL124W YDL021W YGR037C 
YML048W YKR029C YCR003W YJL181W 
YDL100C YLR242C YNL064C YDR146C 
YJR043C YIL160C YAL010C YLR439W 
YBR103W YOR304W YLR420W YDL101C 
YGL033W YGL027C YOR360C YPL203W 
YML041C YJL180C YCR036W YNL010W 
YJL062W YCR068W YNL271C YDR202C 
YIL034C YOL089C YGL133W YCL050C 
YGL194C YBL006C YMR081C YDL020C 
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Overlap sensitive strains to Azole 
in Saccharomyces cerevisiae in two different labs. 
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YAL059W YKL166C YPL195W 
YBL089W YKR030W YPL273W 
YBR114W YKR074W YPR133W-A 













































































































Strains sensitive to Azole and AMB 
in Candida glabrata
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Sensitive AMB Standard 
Name 






































Overlap of sensitive strains between C. albicans , S. 











  100 
Overlap between 
C. albicans and S. 
cerevisiae 
Overlap between S. 
cerevisiae and C. 
glabrata 
Overlap between 
C. albicans and C. 
glabrata 
Overlap between 
C. albicans , S. 
cerevisiae and C. 
glabrata 
YBR126C YAL013W Non YDR389W 
YCR036W YDR293C   
YCR068W YGL027C   
YDR245W    
YGR276C    
YHR168W    
YIL124W    
YLR113W    
YMR283C    
YNL055C    
YNL323W    
YOR067C    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
